Related Experiment Video
Updated: Jun 16, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Incorporating external risk information with the Cox model under population heterogeneity: applications to
1Department of Biostatistics, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48109, USA.
Abstract:
Polygenic hazard scores (PHS) designed for European ancestry (EUR) individuals provide ample information regarding risk discrimination. Incorporating such information can improve the performance of risk discrimination in the target small-sized non-EUR cohort. However, given that external EUR-based PHS and internal individual-level data come from different populations, ignoring population heterogeneity can introduce substantial bias. In this article, we develop a Kullback-Leibler-based Cox model (CoxKL) to integrate internal individual-level time-to-event data with external risk scores derived from published prediction models. Partial-likelihood-based KL information is utilized to measure the discrepancy between the external risk information and the internal data. We establish the asymptotic properties of the CoxKL estimator. Simulation studies show that the integration model by the proposed CoxKL method achieves improved estimation efficiency and prediction accuracy. We apply the proposed method to develop transancestry PHS models for prostate cancer and breast cancer and find that integrating EUR-based PHS with internal genotype data of African ancestry individuals yields considerable improvement on the cancer risk discrimination.
Related Concept Videos
Polygenic Traits
Polygenic Traits
Analysis of Population Pharmacokinetic Data
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio
For example, in a clinical trial evaluating a...
